Publications & Patents

Publications & Patents

Total 85건 3 페이지
Publications & Patents 목록
No. 제목
55
Publication

Clin Cancer Res.

2019

AbstractPurpose: Given that osimertinib is the only approved third-generation EGFR-TKI against EGFR activating and resistant T790M mutated non-small cell lung cancer (NSCLC), additional mutant-selective inhibitors with a higher efficacy, especia…

24.02.20 483
54
Publication

Lung Cancer

2019

AbstractBackground: With the advance of immunotherapy, treatment of non-small-cell lung cancer (NSCLC) has revolutionized by having anti-PD-1 therapy in front-line setting. In this era of cancer immunotherapy, humanized mouse models which recapitulate hum…

24.02.20 558
53
Publication

Sci Rep

2019

AbstractAdequate preclinical model and model establishment procedure are required to accelerate translational research in lung cancer. We streamlined a protocol for establishing patient-derived cells (PDC) and identified effective targeted therapies and novel …

24.02.20 480
52
Publication

Ann Oncol

2019

AbstractBackground: Immune checkpoint blockade with Programmed cell death 1 (PD-1)/PD-L1 inhibitors has been effective in various malignancies and is considered as a standard treatment modality for patients with non-small-cell lung cancer (NSCLC). However…

24.02.20 461
51
Publication

Journal of Cancer Research and Clinical Oncology

2018

AbstractPurpose: Immune checkpoint inhibitors (ICI) have shown marked responses in patients with non-small cell lung cancer (NSCLC) in clinical trials. However, because such trials comprise cohorts selected based on specific criteria, it is unclear if the…

24.02.20 334
50
Publication

Cancer Research

2018

AbstractAnaplastic lymphoma kinase (ALK) inhibitors are highly effective in patients with ALK fusion–positive lung cancer, but acquired resistance invariably emerges. Identification of secondary mutations has received considerable attention, but most…

24.02.20 367
49
Publication

Lung Cancer

2018

AbstractBackground: Preclinical models that can better predict therapeutic activity in clinical trials are needed in this era of personalized cancer treatment. Herein, we established genomically and clinically annotated patient-derived xenografts (PDXs) f…

24.02.20 296
48
Publication

J Thorac Oncol

2017

AbstractBackground: Anaplastic lymphoma receptor tyrosine kinase gene (ALK) fusion is a distinct molecular subclassification of NSCLC that is targeted by anaplastic lymphoma kinase (ALK) inhibitors. We established a transgenic mouse model that expresses t…

24.02.20 331
47
Publication

Oncotarget

2016

AbstractProfilin-like protein in Toxoplasma gondii (TgPLP) is a Toll-like receptor (TLR) agonist. In this study, we investigated whether TgPLP has an adjuvant effect on immune function in autologous whole-tumor-cell vaccine (AWV) treatment. Mice vaccinated wit…

24.02.20 339
46
Publication

Oncogenesis

2016

AbstractAberrant fibroblast growth factor receptor (FGFR) activation/expression is a common feature in lung cancer (LC). In this study, we evaluated the antitumor activity of and the mechanisms underlying acquired resistance to two potent selective FGFR inhibi…

24.02.20 386
45
Publication

Scientific reports

2016

AbstractTo investigate the expression of programmed death-ligand 1 (PD-L1) and immune checkpoints and their prognostic value for resected head and neck squamous cell cancer (HNSCC). PD-L1 expression on tumor cells (TC) and tumor-infiltrating immune cells (IC),…

24.02.20 419
44
Publication

Lung Cancer

2016

AbstractObjectives: The epidermal growth factor receptor (EGFR) abnormalities including amplification, mutation, and overexpression are frequent in non-small cell lung cancer (NSCLC). We investigated in vitro and in vivo antitumor activity of ER2, a novel…

24.02.20 513
43
Publication

Oncotarget

2015

AbstractThe purpose of this study was to investigate the clinical activity, safety and predictive biomarkers of dacomitinib, an irreversible pan-HER inhibitor, in patients with recurrent or metastatic esophageal squamous cell carcinoma (R/M-ESCC). Patients, wh…

24.02.20 440
42
Publication

Mol Cancer Ther

2015

AbstractRET rearrangement is a newly identified oncogenic mutation in lung adenocarcinoma (LADC). Activity of dovitinib (TKI258), a potent inhibitor of FGFR, VEGFR, and PDGFR, in RET-rearranged LADC has not been reported. The aims of the study are to explore a…

24.02.20 398
41

검색